4D Molecular Therapeutics, Inc. 8-K

What Happened
4D Molecular Therapeutics (FDMT) filed an 8-K (Item 5.02) reporting that on March 25, 2026 the board appointed Kristian Humer, age 51, as the company’s Principal Accounting Officer, effective immediately. Mr. Humer has served as the company’s Chief Financial Officer and Principal Financial Officer since November 2025 and succeeds Ashoo Gupta, who will continue as Vice President, Finance and Controller. The report was filed on March 30, 2026.

Key Details

• Appointment effective date: March 25, 2026. 8-K filed March 30, 2026 (Item 5.02).
• Appointee: Kristian Humer, age 51; previously FDMT Chief Financial Officer and Principal Financial Officer since Nov 2025.
• Succession: Mr. Humer succeeds Ashoo Gupta, who remains VP, Finance and Controller.
• Relevant background: CFO at Foghorn Therapeutics (Apr 2024–Nov 2025); CFO & Chief Business Officer at Viridian Therapeutics (Jul 2021–Sep 2023); various roles at Citigroup Global Markets Inc. (Jan 2010–Jul 2021, MD from Dec 2016–Jul 2021). Education: MBA from Duke Fuqua; BA (Hons) in Accounting & Economics, University of Reading.

Why It Matters
This 8-K documents an internal finance leadership change and clarifies who holds the company’s principal accounting responsibilities. For investors, the filing signals continuity in FDMT’s finance team (Humer already served as CFO/PFO) and preserves institutional knowledge with Ashoo Gupta remaining as Controller. The filing does not disclose compensation changes or other material terms beyond the appointment.